Overview
NVP-BEP800, a new HSP90 inhibitor, has particularly interesting therapeutic potential and represents hope in cancer pathologies. While it is currently being tested for solid cancers, no preclinical study has yet demonstrated its effectiveness in acute lymphoblastique leukemia (ALL). The investigators wish to study the effects of NVP-BEP800 on two different types of ALL (T and B-ALL).
Eligibility
Inclusion Criteria:
- Patient suffering from acute lymphoblastic leukaemia whose biological samples are kept at the Biology Technical Platform.
Exclusion Criteria:
- Patient over 80 years of age